ArticleJournal of clinical medicine2022
Clinical Comparison of a Novel Balloon-Expandable Versus a Self-Expanding Transcatheter Heart Valve for the Treatment of Patients with Severe Aortic Valve Stenosis: The EVAL Registry.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Stroke Risk After Bioprosthetic Aortic Valve Replacement in Aortic Stenosis: Systematic Review and Meta-Analysis.Stroke · 2026Pooled it
- Myval versus Contemporary Valves in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.Anatolian journal of cardiology · 2025Pooled it
- Comparative outcomes of Myval versus contemporary transcatheter heart valves: a systematic review and meta-analysis.Cardiovascular intervention and therapeutics · 2025Pooled it
- Perioperative Risk Factors for Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Comparison of Clinical Outcomes of Myval vs. Acurate Neo Valves in TAVR: A Single-Center Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Safety and effectiveness of balloon-expandable Myval transcatheter aortic valve implantation: a single-center, real-world evidence from Kazakhstan.Journal of cardiothoracic surgery · 2026Observational
- Initial Experience With Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis in Nicaragua.Cureus · 2026Article
- A comparison of transcatheter aortic valve prosthesis platforms: Myval, Sapien, and Evolut in severe symptomatic aortic stenosis and low-moderate risk patients.Radiology and oncology · 2025Article
- Head-to-Head Comparison of Meril Myval Series Balloon-Expandable and Abbott Portico Series Self-Expanding Transcatheter Aortic Valves-A Single-Center Experience.Medicina (Kaunas, Lithuania) · 2025Observational
- A systematic review and meta-analysis of the hemodynamics and outcomes of the Myval balloon-expandable valve in patients with severe aortic stenosis and with aortic regurgitation.International journal of cardiology. Heart & vasculature · 2025Article
- Article
- Single-Center Evaluation of the Myval Balloon-Expandable Transcatheter Heart Valve: A Follow-Up Study: A Retrospective Cohort Study.Health science reports · 2025Article
- Myval Transcatheter Heart Valve: The Future of Transcatheter Valve Replacement and Significance in Current Timeline.Journal of clinical medicine · 2024Review
- A new and easy parameter to predict the requirement for permanent pacemaker implantation after transaortic valve implantation: aortic knob calcification.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2024Article
- Comparing outcomes of balloon-expandable vs. self-expandable valves in transcatheter aortic valve replacement: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study.Archives of medical science : AMS · 2024Article
- Assessing the Novel Myval Balloon-Expandable Valve with the Evolut Valve: A Propensity-Matched Study.Journal of clinical medicine · 2023Article
- Myval: A Novel Transcatheter Heart Valve for the Treatment of Severe Aortic Stenosis.Interventional cardiology (London, England) · 2023Review
- Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up.Frontiers in cardiovascular medicine · 2023Article
- Technical Success after Transcatheter Aortic Valve Replacement for Bicuspid versus Tricuspid Aortic Stenosis.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) is an effective treatment option for patients with severe, symptomatic AS, regardless of the transcatheter heart valve (THV) implanted. Prior studies demonstrated a higher device success with lower paravalvular leak (PVL) using the balloon-expandable (BE) Sapien/XT THV vs. a self-expanding (SE) THV. However, few data are available on the performance of a novel BE THV. PURPOSE: to compare early clinical performance and safety of the newly available BE Myval THV (Myval, Meril Life Sciences Pvt. Ltd., India) vs. the commonly used SE (Evolut R, Medtronic) THV.
methods A single-center, retrospective cohort analysis was performed with 166 consecutive patients undergoing TAVR from March 2019 to March 2021 for severe symptomatic AS treated with either the novel BE Myval or the SE Evolut R (ER) bioprosthesis. The primary endpoint was device success at day 30 according to the Valve Academic Research Consortium-3 (VARC-3). Secondary endpoints included 30-day all-cause mortality, cardiovascular mortality, more than mild PVL, permanent pacemaker implantation (PPI) rates and a composite of all-cause mortality and disabling stroke at 6 months.
results Among the 166 included patients, 108 patients received the SE ER THV and 58 patients were treated with the BE Myval THV. At baseline, the two groups showed comparable demographic characteristics. The primary composite endpoint of early device success occurred in 55 patients (94.8%) in the BE Myval group and in 90 patients (83.3%) in the SE ER group (OR 3.667, 95% CI 1.094-12.14;
conclusionsIn patients with severe symptomatic AS undergoing TAVR, the novel Myval BE THV provided a comparable performance to the well-known ER SE THV, and it was associated with a lower rate of PPI and ≥moderate PVL within 30 days and 6 months after the procedure. Randomized, head-to-head comparison trials are needed to confirm our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.